ERBB2 and cervical squamous intraepithelial neoplasia: However, in line with previous reports, our data show that the p53+ subtype (equivalent to CIN or MSS/TP53−) is enriched for HER2 amplification/alterations [13]; therefore, a subset of these patients could be candidates for Trastuzumab or anti-HER2 therapies.